LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

UroGen Pharma Ltd

Open

6.02 20.16

Overview

Share price change

24h

Current

Min

4.96

Max

6.24

Key metrics

By Trading Economics

Income

-6.3M

-44M

Sales

-4.3M

20M

EPS

-0.92

Profit margin

-216.466

Employees

234

EBITDA

-6.2M

-37M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+295.53% upside

Dividends

By Dow Jones

Next Earnings

12 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-296M

223M

Previous open

-14.14

Previous close

6.02

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

UroGen Pharma Ltd Chart

Past performance is not a reliable indicator of future results.

Related News

16 May 2025, 19:39 UTC

Major Market Movers

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

Peer Comparison

Price change

UroGen Pharma Ltd Forecast

Price Target

By TipRanks

295.53% upside

12 Months Forecast

Average 20.33 USD  295.53%

High 36 USD

Low 3 USD

Based on 7 Wall Street analysts offering 12 month price targets forUroGen Pharma Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

5

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

9.625 / 11.64Support & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Neutral Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About UroGen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.